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Abstract
Skin-infiltrating T-cells play a predominant role in allergic and inflammatory skin diseases such as atopic dermatitis, psoriasis
and allergic contact dermatitis. These T-cells are attracted by several chemotactic factors including the chemokine CCL5/
RANTES,a CC chemokine inducing both the migration and activation of specific leukocyte subsets. CCL5 has been found to be
associated with various cell-mediated hypersensitive disorders such as psoriasis, atopic dermatitis and irritant contact
dermatitis. Wehave usedtwoantagonists, the first,Met-CCL5,a dual CCR1/CCR5antagonist and the second, a variant in which
GAG binding is abrogated,
44AANA
47-CCL5, which acts as a dominant negative inhibitor of CCL5. The antagonists were tested
in two models of contact skin reaction. The first, irritant contact dermatitis (ICD) is a pathological non-specific inflammatory
skin condition arising from the release of pro-inflammatory cytokines by keratinocytes in response to haptens, usually
chemicals. The second, contact hypersensitivity (CHS) is a T-cell dependent model, mimicking in part the T-cell-mediated skin
diseases such as psoriasis. In both models, the CCL5 antagonists showed therapeutic efficacy by reducing swelling by 50% as
well as the reduction of soluble mediators in homogenates derived from challenged ears. These results demonstrate that
blocking the receptor or the ligand are both effective strategies to inhibit skin inflammation.
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Introduction
Chemokines are a large family of small structurally homologous
cytokines that stimulate leukocyte movement and regulate migra-
tionof leukocytes from the blood to the tissue. Since the discovery of
the super-family of chemokinesand their receptors, there has been a
considerable effortto definetheir particular roleinthe orchestration
of leukocyte trafficking. Using a varietyof experimental approaches,
evidence has been provided that chemokines are essential mediators
in the pathophysiology of inflammatory diseases and thus good
candidates for therapeutic intervention strategies [1].
Chemokines play a pivotal role in cellular recruitment through
interactions with both cell surface G protein-coupled receptors and
glycosaminoglycans (GAGs) [2]. Specific GAG binding sites of
several chemokines have been delineated by mutagenesis, demon-
strating that these sites are either distinct, or partially overlap with
receptor binding sites. For CCL5 the predominant binding site has
been shown to be the BBXB motif in the 40s loop [3]. The variant
[
44AANA
47]-CCL5, in which the three basic residues in this motif
are mutated to alanine, loses 80% of its capacity to bind to the GAG
heparin in vitro as compared with wild-type CCL5 [2,3].
The recruitment of T cells and other leukocytes to the site of
skin inflammation is a critical step for an efficient response to
potentially dangerous signals as well as in the pathogenesis of
chronic inflammatory skin diseases [1]. A hallmark of autoimmune
skin diseases is the over-expression of chemokines resulting in a
detrimental local accumulation of pro-inflammatory immune cells
[2]. Cytokines and chemokines have a fundamental role in the
regulation of leukocyte trafficking. The chemokine-chemokine
receptor system is highly redundant and forms a complex network
relevantly involved in the expression of inflammatory skin diseases,
including irritant contact dermatitis, atopic dermatitis, allergic
contact dermatitis and psoriasis. The pattern of chemokine
expression shows overlapping features but also important
differences in these diseases due to distinct sources and types of
pro-inflammatory signals involved in chemokine induction and the
inherent capacity of resident skin cells to produce chemokines.
Various studies have documented a strong chemokine expression
in psoriatic skin lesions [1,4,5,6]. Specifically, CXCL8/IL-8 and
the related CXCL2/Gro-b are strongly up-regulated in psoriatic
skin and are responsible for the typical intra-epidermal collection
of neutrophils. CCL2/MCP-1, and CCL5, attract predominantly
monocytes as well as T cell subsets and CXCR3 ligands attract
Th1 cells [1,4,7,8].
The underlying pathogenesis involves three predominant and
interdependent biologic processes: inflammation, epidermal hyper-
proliferation, and altered differentiation with parakeratosis. The
homeostasisof the normalepidermisdependsona balanceof growth
regulatory signals, which are altered in psoriatic epidermis [9].
The aim of this study was to evaluate the therapeutic efficacy
and the immunological response in irritant contact dermatitis
(ICD) and contact hypersensitivity (CHS) mouse models of the
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inflammatory skin condition, arising from the response of pro-
inflammatory cytokines by keratinocytes in response to haptens,
usually chemicals [10,11]. CHS is a T-cell-dependent model,
mimicking T-cell mediated skin diseases, such as psoriasis.
It has been previously shown that Met-CCL5, an N-terminally
modified human-CCL5 that inhibits against activity at two rodent
chemokine receptors CCR1 and CCR5 [12] is effective in a
number of disease models [13]. More recently [
44AANA
47]-CCL5
was shown to be a potent inhibitor of cellular recruitment
confirmed by direct visualization of inhibition of cell rolling and
adhesion using intravital microscopy [2]. The variant showed a
mechanism of action based on disruption of GAG binding and
oligomerization, that results in specific sequestration of CCL5 [2].
In order to demonstrate that blocking the receptor or the ligand
are both effective strategies to inhibit skin inflammation, the
variants were tested in the two mouse models of contact skin
reaction (ICD and CHS), described above. These models were
chosen because chemokines, in particular CCL5, facilitate direct
communication between the innate and adaptive immune
responses and are known to act as key mediators during the full
development of the inflammatory response in skin diseases.
Materials and Methods
Animals
Balb/c female mice, 8–12 weeks of ages, were used to evaluate
the efficacy and the immunological response of the [
44AANA
47]-
CCL5 and Met-CCL5 in ICD and CHS mouse models.
Animals were obtained from Charles River Laboratory (Calco,
Italy) and housed under constant environmental conditions. All in
vivo studies were performed according to the European Council
Directive 86/609/EEC and the Italian Ministry guidelines for care
and use of experimental animals (decree # 116/92). All
experimental protocols were authorized by the Italian Ministry
of Health (decree # 111/2004 B).
Reagents
Both variants [
44AANA
47]-CCL5 and Met-CCL5 were pro-
duced at the Merck-Serono Pharmaceutical Research Institute,
Geneva, Switzerland, as previously described [2,12]. Dexameth-
asone (Soldesam, pharmaceutical preparation), used as reference
compound, was provided by Lab.Farmacologico, Milan, Italy.
The following haptens and irritant were used: 1-fluoro-2,4-
dinitrobenzene (DNFB) (Sigma, St Louis, MO), 4-ethoxymethy-
lene-2phenyl-2-oxazolin-5-one (Oxazolone) (Sigma, St Louis,
MO), Croton oil (Fluka,Chemika, Switzerland).
Commercial human Myeloperoxidase (MPO) and 5-Bromo-2-
Deoxyuridine (BrdU) were obtained from Sigma, St Louis, MO.
For cytokines analyses, BD
TM Cytometric Beads Assay (CBA)
Mouse Inflammation Kit and Mouse Th1/Th2 Cytokine CBA Kit
were used and obtained from Becton Dickinson, BD Biosciences/
Pharmingen, San Diego, CA.
For immunostainings: Rabbit Polyclonal Antibodies against
mouse keratin 6 (K6), mouse keratin 10 (K10) and mouse keratin
14 (K14) (Covance- Prodotti Gianni, Italy), Rabbit pAb IgG (code
AB27478, Abcam); Polyclonal Rabbit Anti-human CD3 (code
A0452, Dako), Negative Control Rabbit Immunoglobulin Fraction
(Normal) (code X 0903, Dako), Vectastain ABC Elite Kit (Vector
Laboratories, Burlingame, CA) and EnVison (Dako) were used.
Experimental Protocol
Contact Hypersensitivity mouse model (CHS) response to
Oxazolone. On day 0 mice were painted on the shaved back
with 50 mL of Oxazolone 3% in acetone/olive oil (4:1). At day 5
mice were challenged by applying 10 mL of Oxazolone 0.5%
in acetone/olive oil (4:1) to each side of the right ear.
Dexamethasone was used as reference compound at 10 mg/kg.
Therapy was applied 30 minutes after challenge by intra-
peritoneal (i.p.) injection.
The specificity of CHS response is generally defined as the
difference between ear swelling responses to a given hapten dose in
naı ¨ve versus sensitized animals [14] mediated by T-cells. A
baseline was done before the irritation. After the treatment,
swelling was followed by measuring the ear thickness. Ear swelling
was calculated as ((Tn – T5) right ear)-(Tn – T5) left t ear)), where
Tn and T5 represent values of ear thickness at day n of
investigation and day 5 prior to challenge, respectively.
In order to label proliferating cells, 24 hours before the sacrifice,
5-Bromo-2-Deoxyuridine (BrdU) (Sigma, St Louis, MO) 200 mg/
kg single dose i.p. was injected.
After 24 hours mice were sacrificed, ear thickness was measured
and ears were homogenized and used for extended analyses.
Contact Hypersensitivity mouse model response to
DNFB. On day 0 mice were sensitized by applying 1-fluoro-2,4-
dinitrobenzene (DNFB) (Sigma, St Louis, MO) 0.5% in Acetone:oil
(4:1) on the shaved back. After 5 days the ear thickness of both ears
at three points each was measured and mice were challenged
with DNFB 0.2% and treated with [
44AANA
47]-CCL5/vehicle/
dexamethasone, as reference compound at 0.5 mg/kg, 30 minutes
after challenge via i.p. injection. 24 hours after challenge mice were
sacrificed, ear thickness was measured and ear swelling was
calculated as described above.
Irritant Contact Dermatitis mouse model (ICD). The
irritant contact dermatitis (ICD) model used was induced by
applying a chemical irritant. On day 0 a 2% solution of Croton oil
(Fluka,Chemika, Switzerland) in acetone/oil (5:1) was applied to
both surface of the right ear.
Mice were treated with the [
44AANA
47]-CCL5 or Met-CCL5/
vehicle/dexamethasone, as reference compound at 0.5 mg/kg, 30
minutes after irritation via i.p. injection. The ear swelling was
followed by measuring the ear thickness of both ears at three time
points and calculating the mean per ear.
For all measurements a caliper (Mytutoyo, Urdorf, Switzerland)
was used.
Six hours after irritation mice were sacrificed and an ear-
punch/ear was taken for further immunological investigations.
Protein extraction. Frozen ears were homogenized,
dissolved in Lysing Buffer (PBS 1X stored at 4uC, Na3VO4,
NaF, NaPir) for 1 h and centrifuged at 13000 rpm, 4uC, for 15
minutes.
Supernatant was collected and protein quantification was done
by Bradford method (Biorad). After quantification, 100 mgo f
extract of each sample were used to perform CBA. Dilutions, if
needed, have been made in sample buffer (Biorad).
Myeloperoxidase (MPO) assay. One punch biopsy of
challenged ears, 5 mm in diameter, was collected by using a
skin punch. Ear biopsy was homogenized and extracted in
Hexadecyltrimethylammonium bromide (HDMA) (Sigma, St
Louis, MO) in 50 uM potassium phosphate buffer (pH 6.5) at a
final concentration of 0.5%. MPO was evaluated by adding at
50 mL of sample, obtained as described above, 50 mLo f1 %
HDMA, 10 mL of o-dianisine at 1.25 mg/mL and 10 mLo f
hydrogen peroxide at 0.05%. The enzymatic reaction was stopped
after 15 minutes and absorbance was measured at 450 nm.
Soluble markers detection. Ears were homogenized and a
protein extraction was performed, as described above. Cytometric
Beads Assay (CBA) Mouse Inflammation Kit (Becton Dickinson,
CCL5/Contact Skin Reaction
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quantitatively measure Interleukin-6 (IL-6), Interleukin-10 (IL-
10), Monocyte Chemoattractant Protein-1 (MCP-1), Interferon-c
(IFN-c), Tumor Necrosis Factor (TNF) and Interleukin-12p70 (IL-
12p70) protein levels in a single sample. As described, Mouse Th1/
Th2 Cytokine CBA Kit (BD) was used to measure Interleukin-2
(IL-2), Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interferon-c (IFN-
c) and Tumor Necrosis Factor-a (TNF-a) protein levels in a single
sample to identify a T-cell mediated immunological profile.
CBA data were analyzed with BD CBA Software, following
manufacture’s instructions. Detection limit of CBA assay is
20 pg/mL.
Tissue processing and immunostaining. Ears were
collected, embedded in paraffin and the fixed sections were
immunostained.
Immunohistochemical staining of keratynocyte proliferation
and differentiation markers (K6 and K10) and CD3 staining were
performed following manufacture’s instructions. Rabbit polyclonal
antibodies against mouse keratin 6 (K6), mouse keratin 10 (K10)
and mouse keratin 14 (K14) (Covance- Prodotti Gianni, Italy),
Rabbit pAb IgG (code AB27478, Abcam); Polyclonal Rabbit Anti-
human CD3 (code A0452, Dako), Negative Control Rabbit
Immunoglobulin Fraction (Normal) (code X 0903, Dako) were
used and the staining was revealed with Vectastain ABC Elite Kit
(Vector Laboratories, Burlingame, CA) and EnVision (Dako).
Histology. Standard protocol for Hematoxilyn-Eosin (H&E)
staining was used.
Statistical analysis. GraphPad Prism4 (San Diego,CA) was
used to perform statistical analyses.
Analysis of variance (ANOVA) followed by Dunnet or
Bonferroni’s post-tests was used. Data were expressed as mean
6 standard error of the mean (SEM) and levels of significance
were assigned as follows: *p,0.05, **p,0.01, ***p,0.001.
Results
Ear Swelling in Oxazolone-Induced CHS
As shown in Fig. 1 the two variants were tested at 0.5 mg/kg in
a head to head comparison CHS time course, using Oxazolone as
hapten. A similar therapeutic potency was observed for the two
compounds. 24 hours after challenge Met-CCL5 at 0.5 mg/kg
was slightly more effective than [
44AANA
47]-CCL5 in terms of
percentage of swelling reduction (54% vs 47%), but statistically the
two variants showed a comparable therapeutic efficacy.
A pronounced ear swelling was observed in the control group
(vehicle), elicited by hapten application 5 days after sensitization.
Fig. 2A) and Fig. 2B) respectively represent the therapeutic effect
on ear swelling of [
44AANA
47]-CCL5 and Met-CCL5 tested at
0.05–0.5–1 mg/kg via i.p.
Dexamethasone 10 mg/kg s.c. was used as reference com-
pound. [
44AANA
47]-CCL5 was able to decrease significantly ear
swelling and a bell shaped dose response was detectable with the
increase of the doses from 1 mg/kg up to 10 mg/kg (data not
shown). Met-CCL5 has shown high activity in decreasing ear
swelling in a dose response modulation.
Ear Swelling in DNFB-Induced CHS
Swelling, as major read-out, was followed after challenge by
measuring ear thickness.
Treatments took place 309 after challenge by intraperitoneal
route at dose of 0.05–0.5–1 mg/kg.
The [
44AANA
47]-CCL5 and Met-CCL5 variants were able to
significantly reduce the swelling 24 h post challenge. Met-CCL5
was slightly more active than [
44AANA
47]-CCL5 at 0.5 mg/kg
(Fig. 2C–D).
Ear Swelling in Irritant Contact Dermatitis (ICD) Mouse
Model
Ear swelling, followed by measuring ear thickness, after hapten
irritation was used as main read-out.
Animals were treated with [
44AANA
47]-CCL5 at doses of
0.5–1–5 mg/kg. The compound was able to significantly reduce
the swelling, starting from 0.5 mg/kg and the maximum
percentage of reduction was reached at 5 mg/kg. (Fig. 2E). Also
treatment with Met-CCL5 was able to significantly reduce the
swelling as shown in Fig. 2F.
Myeloperoxidase Activity in ICD and CHS Ear Extracts
In ICD mouse model [
44AANA
47]-CCL5 at 1 and 5 mg/kg
decreased significantly MPO activity to a similar level as
Dexamethasone which was used as reference compound. The
maximum percentage of reduction was 72.24% (27.76% of
vehicle) at 1 and 5 mg/kg.
Met-CCL5 was able to decrease MPO activity, but not in a dose
dependent manner (Fig. 3A and Fig. 3B respectively).
An important reduction of MPO activity was observed in a
T-cells dependent model of skin inflammation (DNFB-induced
CHS) by [
44AANA
47]-CCL5 at 1 mg/kg (46.6% (53.4% of
vehicle) (Fig. 3C).
As well as treatment with Met-CCL5 at 0.5 mg/kg and
1 mg/kg showed a maximum percentage of reduction close to
50% (44.20% of vehicle and 50.58% of vehicle respectively)
(Fig. 3D).
Cytokine and Chemokine Profiles in ICD and CHS Ear
Extracts
Modulation of pro-inflammatory cytokines in ICD mouse
model is shown in Figure 4A.
CBA assay was performed on ear extracts of Balb/c female
8–12 weeks of age.
Figure 1. Therapeutic efficacy of [
44AANA
47]-CCL5 and Met-
CCL5 on ear swelling. Ear Swelling in head to head Oxazolone-
induced CHS. CHS was induced by sensitization on shaved back with
3% Oxazolone at day 0. Challenge with 0.5% Oxazolone was done at
day 5 to the right ear of sensitized mice. Mice were treated 309 after
irritation once with CCL5 antagonists at 0.5 mg/kg ip. Dexamethasone
10 mg/kg was used as reference compound. Results are given as mean
6 SEM of n=8 mice per group. All statistical analyses were performed
using two-way ANOVA followed by Bonferroni’s post test (***p,0.001
vs vehicle for each time point- 24,48,72 h).
doi:10.1371/journal.pone.0008725.g001
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44AANA
47]- CCL5 at 0.5–1–
5 mg/kg, Met-CCL5 at 0.05–0.1–0.5 i.p.
[
44AANA
47]- CCL5 at 5 mg/kg was able to reduce significantly
levels of IL-12p70 (*p,0.05), IL-6 (**p,0.01) and MCP-1
(**p,0.01).
A trend to reduction has been observed for IL-6 and MCP-1 at
1 mg/kg dose. TNF-a was below detection limit (20 pg/mL)
(Fig. 4A panel 1).
Treatment with Met-CCL5 at 0.05–0.1–0.5 mg/kg was able to
significantly reduce IL-6 (**p,0.01) and MCP-1 (**p,0.01,
*p,0.05). A trend to reduction is shown for IL-12p70. TNF-a
was below detection limit (20 pg/mL) (Fig. 4A panel 2).
Results are given as mean 6 SEM of n=4 mice per group. All
statistical analyses were performed using one-way ANOVA
followed by Dunnett’s multiple comparison test (*p,0.05,
**p,0.01 vs vehicle).
Figure 4B shows the analysis of cytokine levels in DNFB-
induced CHS.
CBA assay was performed on ear extracts of sensitized and
challenged Balb/c female 8–12 weeks of age. Treatments used
are represented by [
44AANA
47]- CCL5 and Met-CCL5 at
0.05–0.5–1 mg/kg ip.
[
44AANA
47]- CCL5 at 1 mg/kg significantly down-modulated
IFN-g and TNF-a (*p,0.05). A trend to reduction for IL-6 and
MCP-1 was observed. Il-12p70 was below detection limit (20 pg/
mL) (Fig. 4B panel 1).
Met- CCL5 at 1 mg/kg significantly reduced IL-6 (*p,0.05).
Trend to reduction was observed for IFNc and MCP-1. TNF-a
and IL-12p70 were under detection limit (20 pg/mL) (Fig. 4B
panel 2).
Results are given as mean 6 SEM of n=4 mice per
group. All statistical analyses were performed using one-way
ANOVA followed by Dunnett’s multiple comparison post test
(*p,0.05).
Evaluation of Infiltrating Inflammatory Cells in
DNFB-Induced CHS
Hematoxilyn and Eosin staining was performed on ear
sections 24 h post challenge (Fig. 5). The panel represent-
ing the vehicle (Fig. 5a) shows a massive infiltration and an
Figure 2. Therapeutic efficacy of [
44AANA
47]-CCL5 and Met-CCL5 on ear swelling, using different mouse models of contact skin
reaction. A) represents [
44AANA
47]-CCL5 and B) Met-CCL5 therapeutic effect respectively on swelling in Oxazolone-induced CHS mouse model at
0.05–0.5–1 mg/kg dose via i.p. Dexamethasone 10 mg/kg sub-cute (s.c.) was used as reference compound. C) represents [
44AANA
47]-CCL5 and D)
Met-CCL5 therapeutic effect respectively on swelling in CHS mouse model using DNFB as hapten at 0.05–0.5–1 mg/kg via i.p. Dexamethasone
0.5 mg/kg s.c. was used as reference compound. E–F) are showing therapeutic efficacy of [
44AANA
47]-CCL5 and Met-CCL5 in ICD mouse model tested
at 0.5–1–5 mg/kg and 0.05–0.1–0.5 mg/kg i.p respectively. Dexamethasone 0.5 mg/kg was used as reference compound. All data were expressed as
mean 6 SEM of n=8/group. All statistical analyses were performed using one-way Anova followed by Dunnett’s multiple comparison post test
(*p,0.05, **p,0.01, ***p,0.001 vs saline-treated vehicle group).
doi:10.1371/journal.pone.0008725.g002
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sia of epithelium, a hallmark of psoriasis. Presence of cellular
infiltrates was observed for the two variants tested at
0.05 mg/kg (Fig. 5b). As shown in Fig. 5 panels c,d
[
44AANA
47]-CCL5 and Met-CCL5 at doses of 0.5 mg/kg and
1 mg/kg, with comparable efficacy, were able to decrease
hyperplasia of epithelium, edema and cellular infiltration to a
similar level as Dexamethasone, used as reference compound
(Fig. 5e).
Evaluation of T-Cells Recruitment in Oxazolone-Induced
CHS
Figure 6 is representing CD3 infiltrates in ear sections in a
Oxazolone-induced CHS. The staining of the vehicle group
revealed an important involvement of T cells (Fig. 6a).
[
44AANA
47]-CCL5 and Met-CCL5 at 0.05 mg/kg (Fig. 6b) were
not able to reduce T cell recruitment. Both variants at 0.5 and
1 mg/kg reduced T-cells infiltrates to similar level as Dexameth-
asone (Fig. 6c/d). The staining revealed no presence of T cells in
ear tissue of animals treated with Dexamethasone 10 mg/kg
(Fig. 6e). Isotype control is shown in Fig. 6f.
Evaluation of Epidermal Alterations in
Oxazolone-Induced CHS
A representative picture of the expression of K6, K10 and K14
is depicted in Figure 7. Using an Oxazolone-induced CHS, in the
present study, we have investigated on keratinocyte proliferation/
differentiation. Fig. 7 panel A shows an important hyperprolifera-
tion and differentiation of keratinocytes in the vehicle group. The
two antagonists at 0.5 mg/kg were able to down-modulate K6 and
K10 expression with a similar potency as shown in Fig. 7 panels B
and C. K14 is constitutively express in basal cells and K14 staining
showed no changes. No hyperproliferation is observed in ear tissue
of animals treated with Dexamethasone (Fig. 7 panel D). Isotype
control is shown if Fig. 7 panel E.
Discussion
A hallmark of inflammatory skin disorders is a massive
recruitment of leukocytes to the site of inflammation. Leukocyte
recruitment is a well-orchestrated process that involves several
protein families, including pro-inflammatory cytokines, adhesion
molecules and chemokines [15].
Figure 3. Myeloperoxidase activity in ICD and CHS ear extracts. Determination of MPO was used as an indirect measure of neutrophils
recruitment and content of ear tissue. Myeloperoxidase activity was tested respectively in ICD and CHS mouse models. In ICD mouse model, one
biopsy of challenged ear (5 mm of diameter) of balb/c 8–12 weeks females was irritated with Croton oil and treated after irritation with A)
[
44AANA
47]-CCL5 at 0.5–1–5 mg/kg and B) Met-CCL5 at 0.025–0.05–0.1–0.5 mg/kg via intraperitoneal injection. In DNFB-induced CHS (Fig. C/D) one
biopsy of challenged ear (5 mm of diameter) of balb/c 8–12 weeks females was challenged by 0.2% DNFB and treated 309 after irritation with
[
44AANA
47]-CCL5 and Met-CCL5 at 0.05–0.5–0.1 mg/kg via intra-peritoneal injection. Results are given in % of vehicle for comparison of therapeutic
efficacy of the two mutants, as mean 6 SEM of n=4 mice.
doi:10.1371/journal.pone.0008725.g003
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assay was performed on ear extracts of Balb/c female 8–12 weeks of age. Panel 1: Treatments used are represented by [
44AANA
47]- CCL5 at 0.5–1–
5 mg/kg ip. [
44AANA
47]- CCL5 at 5 mg/kg was able to reduce significantly levels of IL-12p70 (*p,0.05), IL-6 (**p,0.01) and MCP-1 (**p,0.01). A trend
to reduction has been observed for IL-6 and MCP-1 at 1 mg/kg dose. Panel 2: Treatments used are represented by Met-CCL5 at 0.05–0.1–0.5 ip. Met-
CCL5 at 0.05–0.1–0.5 mg/kg was able to significantly reduce IL-6 (**p,0.01) and MCP-1 (**p,0.01, *p,0.05). A trend to reduction is shown for IL-
12p70. Results are given as mean 6 SEM of n=4 mice per group. All statistical analyses were performed using one-way ANOVA followed by
Dunnett’s multiple comparison test (*p,0.05, **p,0.01 vs vehicle). B) Cytokine and Chemokine profiles in DNFB-induced CHS. CBA assay was
performed on ear extracts of sensitized and challenged Balb/c female 8–12 weeks of age. Panel 1: Treatments used are represented by [
44AANA
47]-
CCL5 at 0.05–0.5–1 mg/kg ip. [
44AANA
47]- CCL5 at 1 mg/kg significantly down-modulated IFN-c and TNF-a (*p,0.05). A trend to reduction for IL-6
and MCP-1. Panel 2: Treatments used are represented by Met- CCL5 at 0.05–0.5–1 mg/kg ip. Met- CCL5 at 1 mg/kg significantly reduced IL-6
(*p,0.05). Trend to reduction was observed for IFNc and MCP-1. Results are given as mean 6 SEM of n=4 mice per group. All statistical analyses
were performed using one-way ANOVA followed by Dunnett’s multiple comparison post test (*p,0.05).
doi:10.1371/journal.pone.0008725.g004
CCL5/Contact Skin Reaction
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8725Figure 5. Evaluation of infiltrating inflammatory cells in ear sections. Haematoxylin and Eosin staining on paraffin ear sections of Balb/c
females 8–12 weeks of age sensitized and challenged in a DNFB-induced CHS. 309 after challenge, mice were treated with [
44AANA
47]-CCL5 and Met-
CCL5 at 0.05–0.5–1 mg/kg ip. Dexamethasone 0.5 mg/kg sc was used as reference compound. 4a) Vehicle group: high level of infiltration,
polymorphonuclear cells (PMN) mostly, dendritic cells (DCs) and Natural Killer cells (NK) as lowest populations. A detail of hyperplasia of epithelium,
represented by an increase in keratinocyte layer thickness is also shown. 4b) Cellular infiltrates and hyperplasia of epithelium are observed in ear
sections of animals treated with [
44AANA
47]-CCL5 and Met-CCL5 at 0.05 mg/kg. 4c)[
44AANA
47]-CCL5 and Met-CCL5 at 0.5 mg/kg were able to
decrease cellular infiltrates, hyperplasia of epithelium (detail shown in the panel) and dermis size (edema) to similar level as Dexamethasone. 4d)
Reduction of cellular infiltrates and keratinocyte layers thickness is observed for [
44AANA
47]-CCL5 and Met-CCL5 at 1 mg/kg. 4e) Dexamethasone
0.5 mg/kg was used as reference compound. 4.1) Control group: not-sensitized, normal skin conditions. In all panels, magnification 206( scale bar:
16.5 mm), details 406(scale bar: 20 mm).
doi:10.1371/journal.pone.0008725.g005
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PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8725Figure 6. Evaluation of CD3 infiltrates in ear sections. Immunostaining with CD3 antibody on ear (paraffin sections) of Balb/c females 8–12
weeks of age sensitized and challenged in a Oxazolone-induced CHS. In all panels, magnification 406(scale bar: 20 mm). A) Vehicle group: the CD3
staining on ear section revealed an important T cells involvement. B) No reduction of T cell infiltrates in ear sections is observed for [
44AANA
47]-CCL5
and Met-CCL5 at 0.05 mg/kg. C–D)[
44AANA
47]-CCL5 and Met-CCL5 at 0.5 and 1 mg/kg respectively were able to reduce T cell involvement to similar
level as Dexamethasone. E) Dexamethasone 10 mg/kg was used as reference compound: clearly no staining is observed. F) Isotype control.
doi:10.1371/journal.pone.0008725.g006
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PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8725Recent studies have provided evidence that chemokines are
essential mediators in the pathophysiologyof inflammatorydiseases,
and are thus good candidates for therapeutic strategies [1].
Modified chemokine peptides have emerged as useful and conve-
nient tools for examining effects of chemokine receptor blockade [16].
In this study we tested two CCL5 antagonists in two models of
contact skin reaction, ICD and CHS, to demonstrate that blocking
the receptor or the ligand are both effective strategies to inhibit
skin inflammation.
In 1997 Texeira and colleagues described a novel mouse model
of eosinophil recruitment in which it was compared the in vivo
chemoattractant activity of different CC chemokines. Their results
demonstrate that Met-CCL5 acts on the mEotaxin receptor
CCR3. When administered systematically, Met-CCL5 inhibited
Figure 7. Expression of keratinocyte proliferation and differentiation markers in ear sections. Immunostaining for keratins was
performed on paraffin sections of ear skin of Balb/c females 8–12 weeks of age sensitized and challenged by Oxazolone. Treatments with [
44AANA
47]-
CCL5 and Met-CCL5 0.5 mg/kg via i.p. took place 309 post challenge. Dexamethasone 10 mg/kg sc was used as reference compound. A) Vehicle:
important hyperproliferation of keratinocyte layer: K6 is widely expressed and it is found supra-basal, K14 is constitutively expressed. K10 showeda n
inverse staining compared to K6. B–C)[
44AANA
47]-CCL5 and Met-CCL5 0.5 mg/kg respectively were able to down-modulate K6 and K10 expression
and to reduce hyperproliferation in a similar manner. K14 staining showed no changes. D) Dexamethasone 10 mg/kg used as reference compound:
clearly no staining is observed. E) Isotype control. In all panels, magnification 206(scale bar: 16.5 mm).
doi:10.1371/journal.pone.0008725.g007
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PLoS ONE | www.plosone.org 9 January 2010 | Volume 5 | Issue 1 | e8725eosinophil recruitment into sites of allergic inflammation in mouse
skin by 68% [17].
These data areconsistentwith ourfindings, althoughweused two
different models of contact skin reaction. In fact, both in ICD, that
results in activation of innate immune response with infiltration in
the ear of mainly neutrophils and macrophages, and in CHS, which
is instead a T cell dependent model of skin inflammation, Met-
CCL5 showed a therapeutic efficacy by reducing swelling by 50%.
Myeloperoxidase (MPO) is an enzyme characteristic for
granulocytes, playing major role in the metabolic activity of
neutrophils [18], localized in the intracellular granules of
neutrophils [19]. We used determination of MPO activity as an
indirect measure of neutrophils recruitment and content of ear
tissue, since the enzymatic activity correlates with the number and
activation state of polymorphonuclear cells (PMN). We observed
in both models reduction of MPO activity by Met-CCL5.
Down-regulation of IL-12p70, IL-6, MCP-1 and IFN-g by Met-
CCL5 in both models of contact skin reaction suggest efficacy of the
compound in modulation of both innate and adaptive responses.
These results were confirmed by histology and immunohisto-
chemistry.
Hematoxilyn and Eosin staining and epidermal analyses using
hyperproliferation and differentiation markers revealed Met-
CCL5 efficacy at 0.5 and 1 mg/kg in decreasing cellular
infiltration and epidermal hyperplasia in ear section as well as
CD3 staining suggested that the compound at 0.5 and 1 mg/kg
was able to modulate adaptive immune responses.
Moreover, it has been published by Elsner et al. that Met-CCL5
demonstrated significant inhibitory effects in acute and chronic
models of tissue inflammation in vivo, reduction of leukocytes
infiltration into affected tissues and an important efficacy in
blocking chemokine-induced effector functions of human eosino-
phils in vitro [20]. It was observed that Met-CCL5 could modify
the composition of leukocyte infiltrates by selective blockade of
CCR1 and CCR5, but it has been shown that blocking chemokine
- chemokine receptor interactions with Met-CCL5 was largely
ineffective in EAE [11].
Recently, it was demonstrated that a CCL5 variant deficient in
GAG binding, [
44AANA
47]-CCL5, antagonizes CCL5-induced
recruitment. This antagonistic property was translated into an
anti-inflammatory effect in a murine model of multiple sclerosis
(MS), experimental autoimmune encephalomyelitis (EAE), in
which its administration before disease onset significantly reduced
clinical symptoms [21].
In our study the antagonistic property of [
44AANA
47]-CCL5
was extended into an anti-inflammatory effect in two murine
models of contact skin reaction.
Swelling was used as indication of edema and subsequent skin
reaction. [
44AANA
47]-CCL5 at 0.5 mg/kg was able to significantly
reduce ear swelling in Oxazolone/DNFB-induced CHS which was
confirmed by a bell shaped dose response detected with the increase
of the doses from 1 to 10 mg/kg in a Oxazolone-induced CHS.
Compound efficacy has been observed also in ICD mouse model.
The maximum percentage of reduction was reached at 5 mg/kg.
Neutrophilsrecruitmentwasmodulated by the compound at 1 and
5 mg/kg in innate and adaptive immune responses. This was
suggested by reduction of MPO activity (72.24% in ICD and 46.6%
in CHS mouse models). The compound was able to down-regulate
pro-inflammatory cytokines. IL-12p70 and IL-6 were down-
modulated in innate responses. As well as [
44AANA
47]-CCL5 at
0.5 and 1 mg/kg was able to reduce IFNc,I L - 6a n dM C P - 1i n
adaptive immune responses. Histology and immunohistochemistry
confirmed compound efficacy at 0.5 and 1 mg/kg in modulation of
innate and adaptive immunity in mouse models of contact skin
reaction. [
44AANA
47]-CCL5 at 0.5 and 1 mg/kg, with comparable
efficacy to Met-CCL5 at same doses, was able to decrease hyperplasia
of epithelium, edema and cellular infiltration to a similar level as
reference compound (Dexamethasone 0.5 mg/kg) As well as CD3
staining revealed an important reduction of T-cells recruitment in ear
tissue of animals treated with [
44AANA
47]-CCL5 at 0.5 and 1 mg/kg
in CHS, which indicate a modulation of adaptive immunity.
These data taken together suggest that both compounds, taking
part with different mechanisms of action, showed therapeutic
efficacy at 0.5 and 1 mg/kg in modulating innate and adaptive
immune responses in mouse models of skin reaction.
It is known from previous literature that specific chemokines
and chemokine receptors have been implicated in inflammatory
demyelinating diseases of the central nervous system (CNS),
including multiple sclerosis (MS) and experimental autoimmune
encephalomyelitis (EAE). Both CCR1 and CCR5 are highly
expressed in the CNS during the active phase of EAE. Met-CCL5
blocks both receptors, but it was demonstrated that Met-CCL5
treatment did not reduce CNS cellular infiltrates or up-regulation
of CCR1 and CCR5 in affected CNS tissues. The variant might
reduce a chemokine-mediated component of CNS macrophage
and microglial activation, thus diminishing axonal pathology and
neurological disability during chronic EAE, but it doesn’t affect the
trafficking of inflammatory hematogenous cells [11].
Based on recent studies confirming the role of CCL5 in the
development and progression of EAE and its up-regulation in
murine EAE, the increased potency of [
44AANA
47]-CCL5 over
Met-CCL5 could be attributed to its proposed mode of action in
that it inhibits oligomerization, a property of CCL5, and Met-
CCL5, that has been shown to induce certain activation events [2].
Additionally, a recent study has implicated a key role for CCL5
in viral-induced demyelination [22]. The significant reduction in
clinical score and delayed onset of disease symptoms in mice
treated with [
44AANA
47]-CCL5 validate an approach involving
disruption of chemokine-GAG interactions as a therapeutic anti-
inflammatory strategy [2].
In summary, with respect to other inflammatory disorders, we
demonstrated that antagonism of CCL5 showed therapeutic
efficacy in models of contact skin reaction, both in a model of
innate immunity (ICD) as well as in models of T-cell mediated skin
pathology (CHS). Then we also demonstrated that the amino-
terminal modified Met-CCL5 gave a pharmacological dose related
effect and it was able to modulate innate immune response as well
as T-cell driven immune responses in ICD and CHS mouse
models. Data are also supported by the immunohistochemical
investigations of keratinocyte pathway and kinetics of inflamma-
tory cells proliferation (data not shown).
In conclusion, this study has been valuable in determining
whether blocking the CCL5 receptor(s), involved in the recruitment
of leukocytes to inflammatory sites, relieves chronic inflammation.
These results demonstrate that blocking the receptor or the ligand
are both effective strategies to inhibit skin inflammation.
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